Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants

被引：24

作者：

Vogel, AM

Lennon, DR

Broadbent, R

Byrnes, CA

Grimwood, K

Mildenhall, L

Richardson, V

Rowley, S

机构：

[1] Univ Auckland, Wellington, New Zealand

[2] Paediat Soc New Zealand, Infect Dis & Immunisat Comm, Wellington, New Zealand

[3] Paediat Soc New Zealand, Fetus & Newborn Comm, Wellington, New Zealand

[4] Paediat Soc New Zealand, Resp Comm, Wellington, New Zealand

来源：

JOURNAL OF PAEDIATRICS AND CHILD HEALTH | 2002年 / 38卷 / 06期

关键词：

consensus; cost effectiveness; palivizumab; preterm; respiratory syncytial virus;

D O I：

10.1046/j.1440-1754.2002.00057.x

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Palivizumab prophylaxis significantly reduces hospitalization for respiratory syncytial virus (RSV) disease in preterm infants. However, palivizumab is very expensive. Data from a New Zealand cost-effectiveness analysis were considered by representatives of the Infectious Diseases and Immunisation, Fetus and Newborn, and Respiratory Committees of the Paediatric Society of New Zealand. Prophylaxis in all high-risk groups was associated with net cost. The consensus panel recommends that the priority for palivizumab be given to babies discharged on home oxygen with chronic lung disease, followed by babies born at 28 weeks or less gestation.

引用

下载

页码：550 / 554

页数：5

共 50 条

[11] Effectiveness of palivizumab in preventing respiratory syncytial virus infection in high-risk children
Viguria, Natividad
Navascues, Ana
Juanbeltz, Regina
Echeverria, Alberto
Ezpeleta, Carmen
Castilla, Jesus
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (06) : 1867 - 1872
[12] Risk of severe respiratory syncytial virus disease, identification of high risk infants and recommendations for prophylaxis with palivizumab
Meissner, HC
Rennels, MB
Pickering, LK
Hall, CB
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2004, 23 (03) : 284 - 285
[13] Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants
Singleton, R
Dooley, L
Bruden, D
Raelson, S
Butler, JC
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2003, 22 (06) : 540 - 545
[14] The frequency of respiratory syncytial virus in high risk infants and the role of palivizumab in prevention of infection
Tom, CM
Touch, SM
Stanley, C
Frey, B
McNett, W
Desai, SA
PEDIATRICS, 1999, 104 (03) : 736 - 737
[15] A Novel Six Consecutive Monthly Doses of Palivizumab Prophylaxis Protocol for the Prevention of Respiratory Syncytial Virus Infection in High-Risk Preterm Infants in Taiwan
Chi, Hsin
Hsu, Chyong-Hsin
Chang, Jui-Hsing
Chiu, Nan-Chang
Hung, Han-Yang
Kao, Hsin-An
Weng, Li-Chuan
Huang, Fu-Yuan
Chiu, Yu-Ying
Chang, Luan-Yin
Huang, Li-Min
PLOS ONE, 2014, 9 (06):
[16] Cost effectiveness of palivizumab for respiratory syncytial virus prophylaxis in high-risk children - A UK analysis
Nuijten, Mark J. C.
Wittenberg, Wolfgang
Lebmeier, Maximilian
PHARMACOECONOMICS, 2007, 25 (01) : 55 - 71
[17] Cost Effectiveness of Palivizumab for Respiratory Syncytial Virus Prophylaxis in High-Risk ChildrenA UK Analysis
Mark J. C. Nuijten
Wolfgang Wittenberg
Maximilian Lebmeier
PharmacoEconomics, 2007, 25 : 55 - 71
[18] BUDGET IMPACT ANALYSIS OF PALIVIZUMAB PROPHYLAXIS FOR THE PREVENTION OF SEVERE RESPIRATORY SYNCYTIAL VIRUS INFECTIONS IN HIGH-RISK INFANTS IN ALGERIA.
Sellam, Y.
Benhalla, K. N.
Boukari, R.
Smati, L.
VALUE IN HEALTH, 2020, 23 : S718 - S718
[19] Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?
Candice Bjornson
Parco Chan
Abby Li
Bosco Paes
Krista L. Lanctôt
Ian Mitchell
European Journal of Clinical Microbiology & Infectious Diseases, 2018, 37 : 1113 - 1118
[20] Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?
Bjornson, Candice
Chan, Parco
Li, Abby
Paes, Bosco
Lanctot, Krista L.
Mitchell, Ian
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2018, 37 (06) : 1113 - 1118

← 1 2 3 4 5 →